Retrospective Study of the Treatment of Urethral Cancer

Tony Y. Eng, Marco Naguib, Timothy Galang, Clifton D. Fuller

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Urethral cancer is rare, encompassing less than 1% of all malignancies. Optimal management, at present, often relies on the limited experience gained from the study of retrospective cases. Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers. A retrospective review of 18 consecutive patients with primary urethral cancer was performed. An analysis was performed of clinical stage, treatment modality, and outcome. Overall patient survival rate for this retrospective was 44%, with a mean follow-up of 63.5 months. Seven of 10 patients with low-stage diagnosis remained disease free. Comparatively, only one of eight patients with high-stage cancer had no apparent disease. Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months). The major characteristic with prognostic impact was statistically found to be low (T1-2, NO, MO) versus high (T3-4, N1, M1) stage, as assessed by Mann-Whimey U test (z = 2.83, p = 0.0023). Clinical staging afforded the strongest prognostic indication of survival. Patients with low-stage disease exhibited increased survival with single-modality therapy. However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.

Original languageEnglish (US)
Pages (from-to)558-562
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number6
DOIs
StatePublished - Dec 2003

Fingerprint

Urethral Neoplasms
Retrospective Studies
Therapeutics
Neoplasms
Radiotherapy
Survival
Disease-Free Survival
Decision Making
Survival Rate
Research Personnel
Drug Therapy

Keywords

  • Clinical staging
  • Non-Hodgkin lymphoma
  • Urethral cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Retrospective Study of the Treatment of Urethral Cancer. / Eng, Tony Y.; Naguib, Marco; Galang, Timothy; Fuller, Clifton D.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 6, 12.2003, p. 558-562.

Research output: Contribution to journalArticle

Eng, Tony Y. ; Naguib, Marco ; Galang, Timothy ; Fuller, Clifton D. / Retrospective Study of the Treatment of Urethral Cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 6. pp. 558-562.
@article{fccfbe4d4dfa4e109de275e5fce44d03,
title = "Retrospective Study of the Treatment of Urethral Cancer",
abstract = "Urethral cancer is rare, encompassing less than 1{\%} of all malignancies. Optimal management, at present, often relies on the limited experience gained from the study of retrospective cases. Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers. A retrospective review of 18 consecutive patients with primary urethral cancer was performed. An analysis was performed of clinical stage, treatment modality, and outcome. Overall patient survival rate for this retrospective was 44{\%}, with a mean follow-up of 63.5 months. Seven of 10 patients with low-stage diagnosis remained disease free. Comparatively, only one of eight patients with high-stage cancer had no apparent disease. Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months). The major characteristic with prognostic impact was statistically found to be low (T1-2, NO, MO) versus high (T3-4, N1, M1) stage, as assessed by Mann-Whimey U test (z = 2.83, p = 0.0023). Clinical staging afforded the strongest prognostic indication of survival. Patients with low-stage disease exhibited increased survival with single-modality therapy. However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.",
keywords = "Clinical staging, Non-Hodgkin lymphoma, Urethral cancer",
author = "Eng, {Tony Y.} and Marco Naguib and Timothy Galang and Fuller, {Clifton D.}",
year = "2003",
month = "12",
doi = "10.1097/01.coc.0000037764.72722.07",
language = "English (US)",
volume = "26",
pages = "558--562",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Retrospective Study of the Treatment of Urethral Cancer

AU - Eng, Tony Y.

AU - Naguib, Marco

AU - Galang, Timothy

AU - Fuller, Clifton D.

PY - 2003/12

Y1 - 2003/12

N2 - Urethral cancer is rare, encompassing less than 1% of all malignancies. Optimal management, at present, often relies on the limited experience gained from the study of retrospective cases. Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers. A retrospective review of 18 consecutive patients with primary urethral cancer was performed. An analysis was performed of clinical stage, treatment modality, and outcome. Overall patient survival rate for this retrospective was 44%, with a mean follow-up of 63.5 months. Seven of 10 patients with low-stage diagnosis remained disease free. Comparatively, only one of eight patients with high-stage cancer had no apparent disease. Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months). The major characteristic with prognostic impact was statistically found to be low (T1-2, NO, MO) versus high (T3-4, N1, M1) stage, as assessed by Mann-Whimey U test (z = 2.83, p = 0.0023). Clinical staging afforded the strongest prognostic indication of survival. Patients with low-stage disease exhibited increased survival with single-modality therapy. However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.

AB - Urethral cancer is rare, encompassing less than 1% of all malignancies. Optimal management, at present, often relies on the limited experience gained from the study of retrospective cases. Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers. A retrospective review of 18 consecutive patients with primary urethral cancer was performed. An analysis was performed of clinical stage, treatment modality, and outcome. Overall patient survival rate for this retrospective was 44%, with a mean follow-up of 63.5 months. Seven of 10 patients with low-stage diagnosis remained disease free. Comparatively, only one of eight patients with high-stage cancer had no apparent disease. Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months). The major characteristic with prognostic impact was statistically found to be low (T1-2, NO, MO) versus high (T3-4, N1, M1) stage, as assessed by Mann-Whimey U test (z = 2.83, p = 0.0023). Clinical staging afforded the strongest prognostic indication of survival. Patients with low-stage disease exhibited increased survival with single-modality therapy. However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.

KW - Clinical staging

KW - Non-Hodgkin lymphoma

KW - Urethral cancer

UR - http://www.scopus.com/inward/record.url?scp=0348134800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348134800&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000037764.72722.07

DO - 10.1097/01.coc.0000037764.72722.07

M3 - Article

C2 - 14663371

AN - SCOPUS:0348134800

VL - 26

SP - 558

EP - 562

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -